Vision Sciences Inc. (NASDAQ:CGNT) has been given a consensus broker rating score of 2.33 (Buy) from the three analysts that cover the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a hold rating and one has given a strong buy rating to the company. Vision Sciences’ rating score has declined by 133% in the last 90 days as a result of a number of analysts’ ratings changes.
Brokerages have set a twelve-month consensus price objective of $4.23 for the company and are anticipating that the company will post ($0.01) EPS for the current quarter, according to Zacks. Zacks has also given Vision Sciences an industry rank of 183 out of 265 based on the ratings given to related companies.
CGNT has been the subject of several research reports. Zacks Investment Research downgraded Vision Sciences from a “hold” rating to a “sell” rating in a research report on Thursday, February 1st. Roth Capital cut Vision Sciences from a “buy” rating to a “hold” rating and set a $4.00 price target for the company. in a research note on Friday, March 23rd. Finally, Aegis cut Vision Sciences from a “buy” rating to a “hold” rating and set a $4.75 price target for the company. in a research note on Tuesday, March 13th.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Meitav Dash Investments Ltd. bought a new position in shares of Vision Sciences in the fourth quarter valued at approximately $1,891,000. White Pine Capital LLC lifted its holdings in Vision Sciences by 233.1% during the fourth quarter. White Pine Capital LLC now owns 244,500 shares of the medical device company’s stock worth $770,000 after acquiring an additional 171,100 shares during the period. Renaissance Technologies LLC lifted its holdings in Vision Sciences by 12.7% during the fourth quarter. Renaissance Technologies LLC now owns 708,637 shares of the medical device company’s stock worth $2,232,000 after acquiring an additional 79,900 shares during the period. Dimensional Fund Advisors LP bought a new stake in Vision Sciences during the third quarter worth $152,000. Finally, Millennium Management LLC lifted its holdings in Vision Sciences by 23.4% during the fourth quarter. Millennium Management LLC now owns 104,343 shares of the medical device company’s stock worth $329,000 after acquiring an additional 19,753 shares during the period. 14.52% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Analysts Anticipate Vision Sciences Inc. (CGNT) to Post ($0.01) EPS” was first reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3341474/analysts-anticipate-vision-sciences-inc-cgnt-to-post-0-01-eps.html.
About Vision Sciences
Cogentix Medical, Inc, a medical device company, designs, develops, manufactures, and markets fiberoptic and video endoscopy products under the PrimeSight brand worldwide. The company offers endoscopes, such as cystoscopes, laryngoscopes, transnasal esophagoscopes, and bronchoscopes for medical use; and borescopes for industrial use, as well as digital processing units for medical use.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vision Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vision Sciences and related companies with MarketBeat.com's FREE daily email newsletter.